MPR2d
Vepdegestrant Beneficial in ER+/HER2- Breast Cancer With ESR1 Mutations
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
Zacks Investment Research on MSN1d
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...
Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?
Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
Arvinas price target lowered to $20 from $82 at BMO Capital
BMO Capital analyst Etzer Darout lowered the firm’s price target on Arvinas (ARVN) to $20 from $82 and keeps an Outperform rating on the ...
Mirage News3d
Arvinas, Pfizer Report Positive Phase 3 VERITAC-2 Results
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant ...
Arvinas stock tumbles despite positive trial results
Arvinas and Pfizer will share the costs and profits of the development and commercialization of vepdegestrant, which has ...
Arvinas, Pfizer announce VERITAC-2 achieved primary endpoint in Phase 3 trial
Arvinas (ARVN) and Pfizer (PFE) announced topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus ...
Seeking Alpha3d
Pfizer, Arvinas post mixed late-stage trial results for breast cancer therapy (update)
The 624-subject global study evaluated patients’ progression-free survival (PFS) as a primary endpoint in the intent-to-treat and estrogen receptor 1-mutant (ESR1m) populations, while their ...
Pharmabiz2d
Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial
Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...